GE HealthCare Technologies (GEHC)
Nasdaq Market Closed
GE HealthCare Technologies Inc. is a global medical technology company best known for diagnostic imaging, ultrasound systems, patient monitoring, and pharmaceutical diagnostics. The company became an independent public company after its separation from General Electric, and it retains a long-standing position in hospital and clinical equipment markets. Its products are used by healthcare providers to diagnose disease, guide treatment decisions, monitor patients, and support care delivery across hospitals, imaging centers, and other medical settings.
The business is organized around four main areas: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Imaging includes modalities such as magnetic resonance, computed tomography, X-ray, molecular imaging, and related service offerings. Ultrasound and visualization technologies support specialties including cardiology, women’s health, emergency medicine, and point-of-care diagnostics. Patient care products include monitoring, anesthesia, and maternal-infant care equipment. Pharmaceutical Diagnostics supplies contrast agents and other products used alongside imaging procedures.
A distinctive feature of GE HealthCare is the mix of capital equipment and recurring revenue. Hospitals purchase large systems that can remain in service for many years, while the company also earns revenue from maintenance, upgrades, consumables, digital tools, and pharmaceutical diagnostic products. This installed base gives the business ongoing customer relationships and exposure to replacement cycles, service contracts, and clinical workflow software.
GE HealthCare operates across major regions including the United States, Europe, the Middle East and Africa, China, and other international markets. Its performance is influenced by hospital capital spending, procedure volumes, healthcare infrastructure investment, regulation, reimbursement trends, and innovation in imaging and digital healthcare. The company competes in markets where reliability, clinical accuracy, service networks, and installed-base scale are critical advantages.
Last updated
- Market Cap
- 29.35B
- P/E
- 15.36
- P/FCF
- 19.37
- P/S
- 1.4
- Enterprise Value
- 37.19B
- Sector
- Health Care
- Industry
- Health Care Equipment
- Address
- 500 WEST MONROE STREET, CHICAGO, IL, 60661
GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.
Bragar Eagel & Squire, P.C. Continues Investigating GE HealthCare Technologies Inc. on Behalf of GE HealthCare Stockholders and Encourages Investors to Contact the Firm
GE HEALTHCARE STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating GE HealthCare Technologies Inc. on Behalf of GE HealthCare Stockholders and Encourages Investors to Contact the Firm
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
Radiochromic Films Market Report 2026-2032: Emerging Trends in Particle Therapy, Industrial Inspections, and Precision Medicine Drive Demand
Refurbished Medical Imaging Equipment Market is expected to generate a revenue of USD 40,056.03 Million by 2032, Globally, at 15.07% CAGR: Verified Market Research®
NXP and GE HealthCare Accelerate AI Innovation in Acute Care
Sterile Bioprocess Filtration Market to Hit USD 21.20 Billion by 2032, Driven by Rising Biologics Production and Adoption of Single Use Filtration Technologies - SNS Insider
Tele-intensive Care Unit Market Size to Reach USD 11.96 Billion by 2032; Growing Advancements in Technology to Propel Market Growth Globally – SNS Insider
Fovia AI to Showcase Universal AI Viewer and Seamless Reporting Integrations at Radiology Reimagined Exhibit, RSNA 2025
Global AI in Medical Imaging Market Set to Surge to USD 4.54 Billion by 2029 | MarketsandMarkets™
AI-Powered Oncology Market Poised to Transform Cancer Care with a 29.36% CAGR by 2034
Cell Harvesting Market to Reach USD 20.08 Billion, Growing at a Strong 12.95% CAGR by 2034
Middle East AI in Oncology Market Size to Hit USD 812.89 Million by 2034
United States AI in Medical Imaging Growth Analysis Report 2025: A $6.76 Billion Market by 2033, Growing at a CAGR of 32.8% Driven by Deep Learning Advances, Rising Data Volumes, and Disease Burdens
Global AI in Medical Diagnostics Market Poised for Phenomenal Expansion at a CAGR of ~22% by 2032 | DelveInsight
Global Smart Medical Devices Market Poised to Expand at a CAGR of ~12% with Technological Advancements and Increased Adoption | DelveInsight
Fetal and Neonatal Care Equipment Market Report 2025-2033 | Compact Designs, Remote Monitoring, and Government & NGO Initiatives Boost Adoption
Saudi Arabia CT Scanners Market Forecast & Opportunities, 2020-2030 | Advanced Imaging Technologies like MDCT, DECT, AI Integration, and Photon-Counting Detectors Drive Growth
Medical Imaging Reagents Market Size to Envision USD 19.32 Billion by 2034
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 29.35B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 37.19B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 15.36
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.75
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.4
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 10.32
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.77
- EPS
- 4.2
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.22%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 19.37
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 14.51
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 1.52B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 17.9%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 5.14%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.95
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.22
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.95
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.27
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 5.53M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 64.51
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 5.13B | 5.7B | 5.14B | 5.01B | 4.78B |
| Gross profit | 1.98B | 2.26B | 1.99B | 1.98B | 2.01B |
| Operating income | 515M | 1.11B | 653M | 726M | 629M |
| EBITDA | 668M | 1.26B | 801M | 874M | 765M |
| Net income | 389M | 589M | 446M | 486M | 564M |
| Basic EPS | 0.85 | 1.29 | 0.98 | 1.06 | 1.23 |
| Diluted EPS | 0.85 | 1.29 | 0.98 | 1.06 | 1.23 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 37.13B | 36.91B | 36.13B | 35.5B | 33.59B |
| Total liabilities | 26.23B | 26.31B | 25.91B | 25.55B | 24.17B |
| Total equity | 10.68B | 10.39B | 10.02B | 9.73B | 9.21B |
| Cash & equivalents | 2.29B | 4.51B | 4.03B | 3.76B | 2.47B |
| Current assets | 10.43B | 12.5B | 11.89B | 11.31B | 9.74B |
| Current liabilities | 8.53B | 9.11B | 10.07B | 9.75B | 9.97B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 286M | 1.05B | 593M | 95M | 250M |
| Investing cash flow | -2.5B | -269M | -149M | -222M | -407M |
| Financing cash flow | 21M | -292M | -165M | 1.36B | -286M |
| Change in cash | -2.23B | 486M | 264M | 1.29B | -416M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SD — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| form 4 | Form 4 — Lobo Kevin | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| form 4 | Form 4 — Bankes Jeannette | View Filing | |
| form 4 | Form 4 — Rackliffe Philip | View Filing | |
| edgar index | SCHEDULE 13G/A — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| form 4 | Form 4 — Hochman Rodney F | View Filing | |
| form 4 | Form 4 — Hochman Rodney F | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 8-K — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Yang Watkin Phoebe L. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — LESJAK CATHERINE A | View Filing | |
| form 4 | Form 4 — Stromberg William J | View Filing | |
| form 4 | Form 4 — Hochman Rodney F | View Filing | |
| form 4 | Form 4 — Hochman Rodney F | View Filing | |
| form 4 | Form 4 — Lobo Kevin | View Filing | |
| form 4 | Form 4 — Madden Anne T | View Filing | |
| form 4 | Form 4 — Madden Anne T | View Filing | |
| form 4 | Form 4 — Yang Watkin Phoebe L. | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — CULP H LAWRENCE JR | View Filing | |
| form 4 | Form 4 — Stromberg William J | View Filing | |
| edgar index | 3 — GE HealthCare Technologies Inc. | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| form 3 | Form 3 — Estrampes Catherine | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| form 4 | Form 4 — SACCARO JAMES | View Filing | |
| edgar index | 8-K — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 10-Q — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | SCHEDULE 13G — GE HealthCare Technologies Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | DEF 14A — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | DEFA14A — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | ARS — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 3 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 8-K — GE HealthCare Technologies Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Lobo Kevin | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing | |
| edgar index | 4 — GE HealthCare Technologies Inc. | View Filing |